Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the

Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in

MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on imp

SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPL

UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and

LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national sharehold

Shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) rose 18.2% on Wednesday after

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

ADAR1 Capital Management LLC acquired a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ:

Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Bu

Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT)

Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular

Maplight Therapeutics NASDAQ: MPLT reported that its Phase II ZEPHYR trial of ML-007C-MA met its pri

MapLight Therapeutics Inc. (NASDAQ:MPLT) stock is trading lower on Monday after the company reported

MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dos

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $MPLT--MPLT Investors Have Opportunity to Join MapLight Therapeutic

MapLight Therapeutics said on Monday its schizophrenia drug failed to show statistically significant

Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's

The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg B

The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg B

UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the

BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) wit

Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the

Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with

SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPL

Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowe

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Auti

Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the

MapLight Therapeutics Inc. (NASDAQ:MPLT) reported mixed topline results from its Phase 2 IRIS study

MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements

The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses plann

SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPL

Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises t

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MapLight Therapeutics (NASDAQ:MPLT)

UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy ra

Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a

MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the

Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results exp

SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT

This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest S

Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an

Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, includ

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (N

The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluatin

Enrollment completed in ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia Last patient visit comple

Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis,

Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrad